Player is loading...
Q&A - On multi-domain approaches for prevention trials
Miia Kivipelto, MD, PhD, Karolinska Institutet
Friday, Oct. 23, 2015 · 1:39 p.m. · 09m 21s
Embed
Transcriptions
Note: this content has been automatically generated.
00:00:00
Oh wow or two so early on top of this
00:00:05
is the whole matrix so I wanna say if
00:00:09
you change Jesse you get this much
00:00:11
reduction change just because once
00:00:13
production surely you can now go back
00:00:16
their files aspects you know and if
00:00:18
you're initially US obviously can't why
00:00:21
we have a certain amount of money. So
00:00:23
we there are those in which is biggest
00:00:26
one Yeah I question we have not yet
00:00:29
check how big clock different
00:00:32
components not explaining you may have
00:00:34
be challenging to do that you
00:00:35
absolutely want to try to see can we
00:00:38
somehow and you know if you make this
00:00:42
value the table what I sold you a all
00:00:44
the population actually put up of risks
00:00:47
at that much the cruel on a per maybe
00:00:49
you remember that no education a small
00:00:52
that if you think globally pack high
00:00:55
value in this country is absolutely
00:00:57
physical activity that has a high just
00:01:00
one when we check that part. but from
00:01:03
what we're yeah I I also got it from
00:01:08
the segments of data such what's that
00:01:12
ask you might a difficult question I
00:01:14
have D do you think do you get if we
00:01:18
had a very fashions oh my god might we
00:01:23
actually they have a few about how much
00:01:27
this something that was more affected
00:01:31
that's I think it was and how far that
00:01:34
point to go. I mean I say a couple of
00:01:39
is that life. But call today and
00:01:43
maintain something something like you
00:01:46
if you have if you I mean I think if we
00:01:51
are thinking prevention embroiled be a
00:01:54
kind of interventions what they showed
00:01:55
you know a cold in a way that this is
00:01:58
something that can be easily
00:02:00
implemented without side effects you
00:02:02
don't take so much streets but more we
00:02:04
are moving a or support them or in in
00:02:06
the bus even more specific treatments
00:02:09
is getting more difficult than there so
00:02:11
probably so that it's difficult to know
00:02:13
what is there but I think many process
00:02:16
one to add maintain the combination but
00:02:19
at the same time is important. It's not
00:02:21
only combination is the quality of life
00:02:23
is the functional capacity as well. So
00:02:26
if I think a sensitive balance there
00:02:28
how how happy and if I'm thinking the
00:02:31
new trials they have like the in
00:02:33
perceived and it's it's really yeah
00:02:36
maybe combining more he's he's he's
00:02:38
he's important. It's important also
00:02:40
just on the use of the patience isn't
00:02:42
that something what we are doing we are
00:02:44
having a lot of call programs that
00:02:46
really trying to involve patience
00:02:49
because we want to know what they want
00:02:51
what type of trial somewhat tripe
00:02:52
interventions on it Is a cult interview
00:02:57
thank you very much. So yeah for this
00:02:59
work that you done for so many years in
00:03:01
this big that the I manipulate on the
00:03:04
on the board that if you so I think we
00:03:08
should for me I think is should be a
00:03:10
difference between statistical
00:03:12
significance it you shown and the
00:03:14
clinical significance critical. And the
00:03:17
significance can be measured different
00:03:19
way so it's not just the the risk
00:03:23
reduction which is important for me but
00:03:25
I think the effects I should be
00:03:27
measured in terms of the delay in the
00:03:29
fonts. So for me I think that it's not
00:03:32
really a that you were gonna say you
00:03:36
that every okay the the chance of
00:03:38
developing the major is lower but it I
00:03:42
think you nobody can really argue that
00:03:45
what you were doing completely apology
00:03:48
the the a risk of developing a major
00:03:52
even in the study that you so no or
00:03:55
that you're referring to the of the
00:03:57
reduction in the incidence of them into
00:03:59
a recently this is of separating by the
00:04:03
fact that more people with old age and
00:04:07
therefore even in these countries where
00:04:09
there is really reduction in the
00:04:11
incidence it but preference of the
00:04:13
manager. We because of the increase so
00:04:16
I think it's important to to talk about
00:04:19
yeah they're talking about the you
00:04:21
mentioned the immediately by Winston
00:04:24
and you were that you were talking
00:04:26
about the use of so many out of this
00:04:28
where but cardiovascular risk factors
00:04:31
are very important preventable a
00:04:34
responsible for the development of the
00:04:35
next year. So my question whether your
00:04:38
intervention will more likely to be
00:04:41
helpful in those people were they
00:04:43
hiding cardiovascular risk then the out
00:04:46
and I think this can tell us something
00:04:48
about the possibly future to yeah about
00:04:52
size is a second question because and
00:04:55
we know I I think there should be a
00:04:58
more in the pretty on the probably
00:05:00
callipers you know we know even a small
00:05:03
change is ED they are more long think
00:05:07
that had a big effect of the population
00:05:10
how to take that on the individual
00:05:12
label is more more difficult but I
00:05:14
think we need to be realistic special
00:05:17
the first estimate if we can even
00:05:19
delayed onset by five or ten years that
00:05:22
would have use effect on that on the
00:05:24
air or the society but I think again at
00:05:27
the individual level is more difficult
00:05:29
to say what ideas. And there is already
00:05:31
a variation normally only show to you
00:05:33
they intended tree analysis but inside
00:05:36
intervention group persons would be not
00:05:38
do as much as we want it so we also
00:05:40
wanted on the lights for that these
00:05:42
data to get more concrete is it makes
00:05:45
about the about the effects. And all
00:05:48
the effect of the intervention for the
00:05:49
possible not we have not seen any clear
00:05:53
de France in we take but it demands the
00:05:56
risk or if you had a find you all all
00:05:58
about you even the individual what's
00:06:00
more effective so at the moment it
00:06:02
seems to be C Miller for the for at
00:06:06
target population of what we had what
00:06:08
we what you do some more what I see
00:06:12
thank use a little more a higher rate
00:06:14
context exactly functions may indicate
00:06:18
that it's possible responsible job yeah
00:06:21
and I would be yeah and I would be
00:06:25
surprised if if this would not be there
00:06:27
because these are the major I lost
00:06:30
reversal candle than you Yeah I thought
00:06:33
that was just a command in the library
00:06:36
where we are pretty sure we or the
00:06:39
mothers of young or we maybe we
00:06:41
complained. And we and we have one more
00:06:47
thing intervention with three off and
00:06:49
got millions of two we are about to to
00:06:52
show that see I was finished quality
00:06:55
time not only improve could be
00:06:58
functional yes that we make give them
00:07:00
an individual because of the market
00:07:03
competition mental no intervention
00:07:05
between must you could do to prevent
00:07:07
yeah yeah yeah and I think it's very
00:07:10
interesting finding a support again
00:07:12
concept and expands findings I think
00:07:16
you know for all the more for a
00:07:18
population so I think it will be ready
00:07:21
with the studies that say we should
00:07:22
really bright more consensus of or
00:07:24
recommendations what's not know what
00:07:26
the different a construct first all
00:07:32
comments for major point the population
00:07:35
is living or and it's a little longer
00:07:38
and speak always public health measures
00:07:41
of the kind that you've shown so like
00:07:43
now waited describe original all who
00:07:46
first point that out smoking is the
00:07:48
cancer and the I thought and that's the
00:07:52
reason the population that so much
00:07:54
longer because oh but I think this your
00:07:57
studies is directly you se exactly.
00:08:01
okay yeah maybe you can you go and
00:08:06
there's no phone on from what the stuff
00:08:10
on that is the morning and what would
00:08:12
you would remain you have all the data
00:08:16
from your own stereo from others I
00:08:19
don't know but probably got in there
00:08:22
you don't you know we got in there why
00:08:24
not populated that unfunded look for
00:08:27
respond with not a ritalin although you
00:08:32
numbers are I you know so and so with
00:08:35
one of the numbers on using more
00:08:37
density yeah that's a good point that's
00:08:40
exactly what we aim to do. So we are
00:08:42
collecting samples and we will when we
00:08:44
put together we have even larger
00:08:46
samples that's why I think the multi
00:08:48
nation that collaboration is important
00:08:50
that we have enough samples. So we we
00:08:52
are doing more inflammatory metabolic
00:08:55
markers cholesterol everything we we
00:08:57
came to find the responders non
00:08:59
responders that's the next step what we
00:09:01
would I don't know I bet you are in a
00:09:05
bar for what she someone to prepare one
00:09:08
last stops. But it's not worse. I want
00:09:11
my whole house also for that but we
Conference Program
Introduction to the 12th Nestlé International Nutrition Symposium
Thomas Beck, NRC Director
Oct. 22, 2015 · 8:57 a.m.
790 views
Introduction to Session I - Cognitive & Brain Development
Susan Gasser, Friedrich Miescher Institute, Basel, Switzerland
Oct. 22, 2015 · 9:04 a.m.
161 views
The development of a healthy brain
Michael Gazzaniga, University of California, Santa Barbara, USA
Oct. 22, 2015 · 9:16 a.m.
398 views
Q&A - The development of a healthy brain
Michael Gazzaniga, University of California, Santa Barbara, USA
Oct. 22, 2015 · 9:56 a.m.
Early influences on brain development and epigenetics
Stephen G. Matthews, University of Toronto, Canada
Oct. 22, 2015 · 10:49 a.m.
154 views
Q&A - Early influences on brain development and epigenetics
Stephen G. Matthews, University of Toronto, Canada
Oct. 22, 2015 · 11:29 a.m.
Building the physiology of thought
Rebecca Saxe, Massachusetts Institute of Technology, Cambridge, USA
Oct. 22, 2015 · 11:38 a.m.
226 views
Q&A - Building the physiology of thought
Rebecca Saxe, Massachusetts Institute of Technology, Cambridge, USA
Oct. 22, 2015 · 12:10 p.m.
Introduction to Session II - Cognitive Decline
Kathinka Evers
Oct. 22, 2015 · 2:02 p.m.
Brain health & brain diseases - future perspectives
Richard Frackowiak, CHUV University Hospital, Lausanne, Switzerland
Oct. 22, 2015 · 2:11 p.m.
120 views
Alzheimer's disease: genome-wide clues for novel therapies
Rudolph E. Tanzi, Massachusetts General Hospital, Charlestown, USA
Oct. 22, 2015 · 3:15 p.m.
Q&A - Alzheimer's disease: genome-wide clues for novel therapies
Rudolph E. Tanzi, Massachusetts General Hospital, Charlestown, USA
Oct. 22, 2015 · 3:59 p.m.
Immunometabolic regulators of age-related inflammation
Vishwa D. Dixit, Yale School of Medicine, New Haven, USA
Oct. 22, 2015 · 4:21 p.m.
160 views
Q&A - Immunometabolic regulators of age-related inflammation
Vishwa D. Dixit, Yale School of Medicine, New Haven, USA
Oct. 22, 2015 · 4:59 p.m.
Introduction to Session III - Nutrition & Cognitive Development
Pierre Magistretti, KAUST, Thuwal, Saudi Arabia and EPFL, Lausanne, Switzerland
Oct. 23, 2015 · 9 a.m.
Energy metabolism in long-term memory formation and enhancement
Cristina M. Alberini, The Center for Neural Science, New York University, USA
Oct. 23, 2015 · 9:16 a.m.
413 views
Q&A - Energy metabolism in long-term memory formation and enhancement
Cristina M. Alberini, The Center for Neural Science, New York University, USA
Oct. 23, 2015 · 9:53 a.m.
Building the costly human brain: implications for the evolution of slow childhood growth and the origins of diabetes
Christopher Kuzawa, Northwestern University, Evanston, USA
Oct. 23, 2015 · 10:29 a.m.
Q&A - Building the costly human brain: implications for the evolution of slow childhood growth and the origins of diabetes
Christopher Kuzawa, Northwestern University, Evanston, USA
Oct. 23, 2015 · 10:57 a.m.
Nutrition, growth and the developing brain
Prof. Maureen Black, University of Maryland, School of Medicine, Baltimore, USA
Oct. 23, 2015 · 11:09 a.m.
152 views
Q&A - Nutrition, growth and the developing brain
Prof. Maureen Black, University of Maryland, School of Medicine, Baltimore, USA
Oct. 23, 2015 · 11:49 a.m.
Introduction to Session IV - Decline & Nutritional Intervention
Tamas Bartfai, The Scripps Research Institute, La Jolla, USA
Oct. 23, 2015 · 12:48 p.m.
179 views
On multi-domain approaches for prevention trials
Miia Kivipelto, Karolinska Institutet, Stockholm, Sweden
Oct. 23, 2015 · 1:04 p.m.
218 views
Q&A - On multi-domain approaches for prevention trials
Miia Kivipelto, MD, PhD, Karolinska Institutet
Oct. 23, 2015 · 1:39 p.m.
Methodological challenges in Alzheimer clinical development
Lon S. Schneider, Keck School of Medicine of USC, Los Angeles, USA
Oct. 23, 2015 · 1:49 p.m.
124 views
Q&A - Methodological challenges in Alzheimer clinical development
Lon S. Schneider, Keck School of Medicine of USC, Los Angeles, USA
Oct. 23, 2015 · 2:32 p.m.
We are what we remember: memory and age related memory disorders
Eric R. Kandel, Columbia University, New York, USA
Oct. 23, 2015 · 3:03 p.m.
230 views
Concluding Remarks
Stefan Catsicas, Chief Technology Officer, Nestlé SA
Oct. 23, 2015 · 3:50 p.m.
168 views